Multiple Sclerosis Relapse Rate Linked to Puberty in Boys
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
Relapsing Remitting Multiple Sclerosis
Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression
Previous MRI studies focused on gray matter changes only.
Alemtuzumab May Reduce Disability in Early MS
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Gut Bacteria Profile Differs in Patients with Multiple Sclerosis
Differences in gut bacteria were apparent between patients with active RRMS and those in remission.
Siponimod Effective in Reducing Disease Activity in Relapsing MS
The 2 mg dose appears to be most efficacious.
Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis
If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.
Anti-LINGO-1 Fails to Meet Primary Endpoint in Multiple Sclerosis
The company said it will continue to explore its options.
Immunosuppressive Therapy Plus Stem Cell Transplant Promising in Severe RRMS
Notably, results were achieved without maintenance therapy.
Next post in CMSC 2016 Coverage
